<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cunningham, Muriel</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Adams, David H.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">TAVR Decreases Mortality When Compared with Surgery in High-Risk Patients</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-13</style></pages><abstract><style  face="normal" font="default" size="100%">A large, prospective, randomized trial was conducted at 45 sites in the United States to compare the safety and efficacy of transcatheter aortic valve replacement (TAVR) with the CoreValve self-expanding prosthesis with surgical aortic-valve replacement (SAVR) in patients with severe aortic stenosis at high risk for cardiac surgery. This article presents the results from the patients in the high-risk cohort who were randomized to either CoreValve or surgery [Adams DH et al. N Engl J Med 2014].</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>